Brief: Hansa Biopharma Announces Positive Reimbursement Decision For Idefirix
01/06/2023 07:25
June 1 (Reuters) - Hansa Biopharma AB HNSA.ST :
* HANSA BIOPHARMA ANNOUNCES POSITIVE REIMBURSEMENT DECISION
FOR
IDEFIRIX (IMLIFIDASE) IN BELGIUM AS DESENSITIZATION TREATMENT
FOR HIGHLY SENSITIZED PATIENTS IN KIDNEY TRANSPLANTATION
* HAS ATTAINED REIMBURSEMENT IN BELGIUM FOR ITS
FIRST-IN-CLASS
TREATMENT, IDEFIRIX
Source text for Eikon: ID:nWkr6VNwQm
Further company coverage: HNSA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS